MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Tenax Therapeutics General and Administrative Expenses 2011-2026 | TENX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.7 M | 6.78 M | 5.01 M | 5.68 M | 7.58 M | 5.31 M | 5.08 M | 5.65 M | 5.68 M | 6.25 M | 7.17 M | 13.8 M | 3.68 M | 6.09 M | 7.68 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 23.7 M | 3.68 M | 7.67 M |
Quarterly General and Administrative Expenses Tenax Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.48 M | 5.67 M | 5.66 M | - | 1.51 M | 1.34 M | 1.23 M | - | 1.05 M | 1.04 M | 1.27 M | - | 1.38 M | 1.34 M | 1.54 M | - | 2.64 M | 1.27 M | 1.37 M | - | 1.17 M | 869 K | -1.32 M | - | -1.34 M | -1.17 M | -1.18 M | - | -1.19 M | -1.58 M | -1.16 M | - | -1.06 M | -1.79 M | -1.45 M | - | -1.27 M | -1.24 M | 1.76 M | 1.91 M | 1.43 M | 1.23 M | 1.37 M | 1.78 M | 1.59 M | 1.59 M | 1.45 M | 1.44 M | 1.42 M | 1.42 M | 983 K | 1.42 M | 423 K | 423 K | 1.26 M | 2.28 M | 1.66 M | 1.66 M | 1.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.48 M | -1.79 M | 1.03 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
186 K | $ 0.81 | -3.11 % | $ 37 M |  Israel |
 |
Exelixis
EXEL
|
519 M | $ 46.21 | -5.11 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
96.4 M | $ 2.43 | -4.71 % | $ 67.8 M | USA |
 |
Heron Therapeutics
HRTX
|
54.6 M | $ 1.24 | -5.73 % | $ 207 M | USA |
 |
InflaRx N.V.
IFRX
|
13.5 M | $ 2.86 | 14.2 % | $ 192 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
394 M | $ 75.53 | -1.72 % | $ 12.1 B | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 92.4 | -3.0 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Kymera Therapeutics
KYMR
|
68.2 M | $ 85.56 | -0.81 % | $ 7.23 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
78.7 M | $ 212.11 | -8.79 % | $ 3.88 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 22.02 | 2.51 % | $ 3.65 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
257 M | $ 100.27 | -8.92 % | $ 5.03 B | USA |
 |
MannKind Corporation
MNKD
|
144 M | $ 3.59 | 0.7 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
166 M | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.65 | 8.96 % | $ 6.01 M | Israel |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | Canada |
 |
Genprex
GNPX
|
6.09 M | $ 0.88 | -1.48 % | $ 821 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
6.88 M | $ 0.65 | -4.03 % | $ 3.56 M | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Nanobiotix S.A.
NBTX
|
19.4 M | $ 43.46 | 3.82 % | $ 286 B | France |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 21.33 | -11.75 % | $ 2.71 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
661 M | $ 27.16 | -2.62 % | $ 16.8 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
10.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |